Dyadic to Present at H.C. Wainwright 23rd Annual Global Investment Conference

by B2i | Sep 10, 2021 | Press Releases

JUPITER, Fla., Sept. 10, 2021 — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ:DYAI), a global biotechnology company focused on further improving, applying, and...

Dyadic Reports Second Quarter 2021 Financial Results and Highlights Recent Company Progress

by B2i | Aug 12, 2021 | Press Releases

Executed binding term sheet with Sorrento Therapeutics (Nasdaq:SRNE) to outlicense C1 protein production platform for the development and commercialization of vaccines, therapeutic antibodies, protein therapeutics, and diagnostics for coronaviruses, including...

Dyadic and Sorrento Announce Binding Term Sheet to License Dyadic’s Lead COVID-19 Vaccine Candidate “DYAI-100” and C1 Technology for Protein-Based Coronavirus Vaccines and Therapeutics

by B2i | Aug 11, 2021 | Press Releases

Sorrento to obtain exclusive rights in North and South America, Europe, major Asian countries (including Greater China and Japan) and certain other countries to utilize Dyadic’s C1 technology for the development and commercialization of vaccines, therapeutic...

Dyadic to Report Second Quarter 2021 Financial Results

by B2i | Jul 29, 2021 | Press Releases

JUPITER, FL / July 29, 2021 / Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ:DYAI), a global biotechnology company focused on further improving, applying and deploying its...

Dyadic Announces Technology Transfer and Licensing Agreement With South Africa’s Rubic Consortium Aiming to Develop and Commercialize Vaccines for Distribution Throughout the African Continent

by B2i | Jul 27, 2021 | Press Releases

Potential for Affordable COVID-19 Immunization Coverage in Underserved African CountriesArrangement includes C1 COVID-19 vaccine technology transfer and licensing agreementProvides potential funding pathway for a C1 manufactured COVID-19 vaccine to progress through...